Skip to main content
    B

    Bio-Rad Laboratories Inc (BIO)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $358.24
    -2.02 (-0.56%)

    Market Cap: $9.69B

    Last updated: Nov 17, 2026 at 4:20 PM ET

    Bio-Rad Laboratories Inc (BIO) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Bio-Rad Laboratories (BIO) has a market cap of $9.69B and an enterprise value of $10.43B. It kept 39.45% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 7.62% above the market cap, as debt exceeds cash.

    Market Cap$9.69B
    Enterprise Value$10.43B
    Latest price (Nov 17, 2026)$358.24

    Key Dates

    The next earnings report is expected on Feb 10, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 10, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.13% in the quarter ended Sep 30, 2026 and shrank 2.11% a year over 2 years.

    Shares Outstanding26.78M
    Other Share ClassesBIO-B
    Shares Change (YoY)-0.53%
    Shares Change (QoQ)+0.13%
    Share Count Growth (2Y CAGR)-2.11%

    Valuation Ratios

    Sales and book value multiples are 3.7x and 1.3x. Its year-end P/E ranged from 27.4x to 191.9x from 2016 to 2025.

    P/E Ratio37.0x
    Forward P/E36.9x
    P/S Ratio3.7x
    Forward P/S3.8x
    P/B Ratio1.3x
    P/TBV Ratio1.4x
    P/FCF Ratio24.4x
    P/OCF Ratio18.2x
    PEG Ratio15.8

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 22.0x EBITDA and 26.3x free cash flow.

    EV / Earnings10.2x
    EV / Sales4.0x
    EV / EBITDA22.0x
    EV / FCF26.3x

    Price Statistics

    The stock is up 14.40% over 52 weeks and trades 3.70% below its 50-day average.

    Beta (1Y)0.73
    52-Week Change+14.40%
    1-Month Change+1.54%
    3-Month Change-1.65%
    6-Month Change+27.46%
    5-Year Change-53.17%
    10-Year Change+135.44%
    Total Return (1Y)+14.40%
    Total Return (3Y CAGR)+6.17%
    Total Return (5Y CAGR)-14.25%
    Return vs SPY (1Y)+4.84%
    Max Drawdown (1Y)-27.24%
    Max Drawdown (3Y)-42.14%
    Sharpe Ratio (1Y)0.42
    Correlation with SPY (1Y)0.28
    50-Day Average$372.00
    200-Day Average$317.63
    52-Week Range$236.73 to $396.23
    RSI (14 Days)41.2
    Average Volume (20 Days)253.29K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.18x current liabilities, and total debt is 0.16x shareholder equity.

    Current Ratio3.18x
    Quick Ratio2.37x
    Debt / Equity0.16x
    Debt / EBITDA2.57x
    Debt / FCF3.06x
    Interest Coverage9.60x

    Returns and Efficiency

    Return on invested capital is 4.12% over the last 12 months, against a 5-year average of 3.02%.

    Return on Equity (ROE)13.45%
    Return on Assets (ROA)9.49%
    Return on Invested Capital (ROIC)4.12%
    ROE (5Y Average)-6.36%
    ROA (5Y Average)-4.13%
    ROIC (5Y Average)3.02%
    Asset Turnover0.25x
    Inventory Turnover1.62x
    Receivables Turnover6.00x
    Cash Conversion Cycle247 days

    Taxes

    Income tax took 22.52% of pretax income over the last 12 months.

    Income Tax (TTM)$297.30M
    Effective Tax Rate22.52%

    Scores

    BIO has an Altman Z-Score of 3.53, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score3.53
    Altman Z ZoneSafe
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $2.59B over the last 12 months is up 1.38% from the 12 months before.

    Revenue$2.59B
    Revenue Growth (YoY)+1.38%
    Gross Profit$1.33B
    Operating Income-$61.90M
    Pretax Income$1.32B
    Net Income$1.02B
    Reported EPS (TTM)$9.67

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 70.50% of the $10.78B in total assets.

    Cash and Equivalents$465.30M
    Total Debt$1.20B
    Net Debt$738.70M
    Net Debt Per Share$27.58
    Working Capital$2.11B
    Shareholder Equity$7.60B
    Book Value Per Share$283.91
    Tangible Book Value$6.93B
    Tangible Book Per Share$258.61
    Total Assets$10.78B
    Total Liabilities$3.18B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $139.00M of capital spending, operating cash flow left $393.00M of free cash flow.

    Operating Cash Flow$532.00M
    Capital Expenditures$139.00M
    Free Cash Flow$393.00M
    FCF Per Share$18.11

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -2.39%, against a 5-year average of 11.86%.

    Gross Margin51.26%
    Operating Margin-2.39%
    Pretax Margin50.92%
    Net Margin39.45%
    FCF Margin15.16%
    Gross Margin (5Y Average)54.20%
    Operating Margin (5Y Average)11.86%
    Net Margin (5Y Average)-10.04%

    Growth

    Revenue fell 2.68% a year over 3 years, and EPS 11.33% a year.

    Revenue Growth (3Y CAGR)-2.68%
    Revenue Growth (5Y CAGR)+0.29%
    EPS Growth (3Y CAGR)-11.33%
    EPS Growth (5Y CAGR)-1.19%
    FCF Growth (5Y CAGR)-4.69%
    Operating Income Growth (3Y CAGR)-53.93%
    Book Value Per Share Growth (2Y CAGR)-4.63%
    Tangible Book Per Share Growth (2Y CAGR)-5.53%

    Revenue and profit by year

    Dividends and Yields

    BIO does not pay a dividend. Its free cash flow yield is 4.10%.

    Earnings Yield2.70%
    FCF Yield4.10%
    Buyback Yield0.67%
    Shareholder Yield0.67%

    Stock Splits

    The last split was a 2-for-1 forward split on Mar 8, 2002.

    Last Split DateMar 8, 2002
    Split TypeForward split
    Split Ratio2:1

    Peer Position

    Against 9 similar companies, BIO has the 3rd highest P/E.

    P/E Ratio37.0x vs 23.6x median
    P/S Ratio3.7x vs 3.5x median
    ROIC4.12% vs 7.96% median
    Revenue Growth (Trailing 4 Quarters, YoY)+1.38% vs +9.91% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 0.46% and EPS growth at -0.07% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+0.46%
    EPS Growth Forecast (2Y CAGR)-0.07%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About BIO

    What is BIO's market cap?

    Bio-Rad Laboratories has a market cap of $9.69B. Its enterprise value, which adds debt and subtracts cash, is $10.43B.

    What is BIO's P/E ratio?

    Bio-Rad Laboratories has a trailing P/E ratio of 37.0x and a forward P/E of 36.9x.

    How many shares of BIO are outstanding?

    Bio-Rad Laboratories has 26.78M shares outstanding. The count is down 0.53% from a year earlier.

    Does BIO pay a dividend?

    No. Bio-Rad Laboratories does not pay a dividend.

    How much debt does BIO have?

    Bio-Rad Laboratories has $1.20B of total debt and $465.30M of cash and equivalents, a net debt position of $738.70M.